Table 1.
Associations between the FcγRIIa and FcγRIIIa polymorphisms and clinical benefit.
| mAb | FcγRIIa-131 Genotype | FcγRIIIa-158 Genotype | Cancer Disease | Total Patients | Clinical Association | Study Reference |
|---|---|---|---|---|---|---|
| Rituximab | – | V/V | FL | 49 | Higher RR | Cartron et al. (11) |
| Rituximab | H/H | V/V | FL | 87 | Higher RR | Weng et al. (12) |
| Rituximab | – | V/V | FL and MCL | 171 | Higher EFS | Ghielmini et al. (13) |
| Rituximab | – | V/V | FL | 66 | Longer OS | Persky et al. (14) |
| Rituximab | – | V carriers | DLBCL | 113 | Higher RR and CR | Kim et al. (15) |
| Rituximab | – | V carriers | DLBCL | 34 | Higher RR Longer OS |
Zhang et al. (16) |
| Rituximab | – | V carriers | NHL | 1050 | Higher CR rate (in Asian patients) | Liu et al. (17) |
| Daratumumab | – | F/F | r/r MM | 148 | Higher RR Longer PFS (in multivariate Cox regression analysis) |
van de Donk et al. (18) |
| Trastuzumab | H/H | V/V | mBC | 54 | Higher RR Longer PFS |
Musolino et al. (19) |
| Trastuzumab | – | V carriers | early-stage BC | 1156 | Longer DFS | Gavin et al. (20) |
| Trastuzumab | H/H | – | early-stage/mBC | 15/35 | Higher RR Longer PFS (only in mBC group) |
Tamura et al. (21) |
| Trastuzumab | H/H or H/R | – | BC | 132 | Higher EFS | Roca et al. (22) |
| Trastuzumab | H/H | V/V | GC | 42 | Longer PFS (for H/H genotype) Higher DCR (for the combination of H/H and V/V genotype) |
Wang et al. (23) |
| Margetuximab | – | F carrriers | mBC | 506 | Longer PFS | Rugo et al. (24) |
| Cetuximab | H/H | V/V | mCRC | 69 | Longer PFS | Bibeau et al. (25) |
| Cetuximab | – | V carriers | mCRC | 52 | Higher RR Longer OS |
Etienne-Grimaldi et al. (26) |
| Cetuximab | H/H or H/R | V carriers | mCRC | 96 | Higher RRLonger PFS (for V/- allele) | Trotta et al. (27) |
| Cetuximab | H/H | F/F | mCRC | 595 | Longer OS(for H/H genotype only or in combination with F/F genotype) | Shepshelovich et al. (28) |
| Cetuximab | H/H | – | mCRC | 293 | Longer PFS and OS | Liu et al. (29) |
| Cetuximab | H/H or H/R | F carriers | mCRC | 39 | Longer PFS | Zhang et al. (30) |
| Cetuximab | – | F carriers | advanced CRC | 58 | Longer OS | Dahan et al. (31) |
| Cetuximab | H/H | – | mCRC | 106 | Higher DCR | Rodriguez et al. (32) |
| Cetuximab | H/H | V/V | recurrent and mHSNCC | 103 | Longer PFS and OS | Magnes et al. (33) |
| Farletuzumab | H/H | V/V | EOC | 461 | Longer PFS in patients with low baseline CA125 levels | Wang et al. (34) |
| Ipilimumab | – | V carriers | Melanoma | 121 | Higher RR | Van Allen et al. (35) Snyder et al. (36) |
| Ipilimumab | – | V carriers | Melanoma | 51 | Longer OS | Snyder et al. (36) |
mAb, monoclonal antibody; mBC, metastatic breast cancer; EOC, epithelial ovarian cancer; mCRC, metastatic colorectal cancer; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; mHSNCC, metastatic head and neck squamous cell carcinoma; MCL, mantle cell lymphoma; r/r MM: relapsed/refractory multiple myeloma; NHL, non-Hodgkin lymphoma; EFS, event-free survival; DCR, disease control rate; OS, overall survival; D/PFS, disease/progression free survival; RR, response rate.